Trans-dermal Form of Combined HormonalContraception (EVRA®)
Authors:
M. Fanta
Authors‘ workplace:
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze, přednosta prof. MUDr. J. Živný, DrSc.
Published in:
Ceska Gynekol 2003; (5): 341-345
Category:
Overview
Objective:
To present a review of a novel transdermal contraceptive patch containing norelgestromin(150 g/d) and ethinylestradiol (20 g/d).Design: Review article.Setting: Department of Gynecology and Obstetric, 1st Medical Faculty and General Faculty Hospital,Prague.Results: The contraceptive patch exhibits favourable pharmakokinetic profile, maintaining efficaciousserum hormone concentrations under varying conditions and without peaks and throughcharacteristic of oral dosing. Efficacy, cycle control, tolerability and side effect profile were comparableto an established oral contraceptive. Compliance with the weekly administered contraceptivepatch was significantly better than with an oral contraceptive. The reliability of adhesion of thepatch is very high and consistent even under varying conditions (heat, humidity, exercise).
Key words:
transdermal contraception, contraceptive patch, norelgestromin, ethinylestradiol
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2003 Issue 5
Most read in this issue
- May-Hegglin Anomaly in Pregnancy. Two Case Report
- Vaginal Birth in Primiparas and Anal Incontinence
- Trans-dermal Form of Combined HormonalContraception (EVRA®)
- What Can the Bethesda System Give to Gynecologistand What is Expected from Them